Literature DB >> 31632773

Hyperprogressive disease with immunotherapy: new directions.

Sally C M Lau1, Natasha B Leighl1.   

Abstract

Entities:  

Year:  2019        PMID: 31632773      PMCID: PMC6783768          DOI: 10.21037/jtd.2019.08.88

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  15 in total

Review 1.  Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells.

Authors:  Zibing Wang; Brian Till; Quanli Gao
Journal:  Oncoimmunology       Date:  2017-06-16       Impact factor: 8.110

2.  Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.

Authors:  Shumei Kato; Aaron Goodman; Vighnesh Walavalkar; Donald A Barkauskas; Andrew Sharabi; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2017-03-28       Impact factor: 12.531

3.  RECIST 1.1-Update and clarification: From the RECIST committee.

Authors:  Lawrence H Schwartz; Saskia Litière; Elisabeth de Vries; Robert Ford; Stephen Gwyther; Sumithra Mandrekar; Lalitha Shankar; Jan Bogaerts; Alice Chen; Janet Dancey; Wendy Hayes; F Stephen Hodi; Otto S Hoekstra; Erich P Huang; Nancy Lin; Yan Liu; Patrick Therasse; Jedd D Wolchok; Lesley Seymour
Journal:  Eur J Cancer       Date:  2016-05-14       Impact factor: 9.162

4.  STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Authors:  Ferdinandos Skoulidis; Michael E Goldberg; Danielle M Greenawalt; Matthew D Hellmann; Mark M Awad; Justin F Gainor; Alexa B Schrock; Ryan J Hartmaier; Sally E Trabucco; Laurie Gay; Siraj M Ali; Julia A Elvin; Gaurav Singal; Jeffrey S Ross; David Fabrizio; Peter M Szabo; Han Chang; Ariella Sasson; Sujaya Srinivasan; Stefan Kirov; Joseph Szustakowski; Patrik Vitazka; Robin Edwards; Jose A Bufill; Neelesh Sharma; Sai-Hong I Ou; Nir Peled; David R Spigel; Hira Rizvi; Elizabeth Jimenez Aguilar; Brett W Carter; Jeremy Erasmus; Darragh F Halpenny; Andrew J Plodkowski; Niamh M Long; Mizuki Nishino; Warren L Denning; Ana Galan-Cobo; Haifa Hamdi; Taghreed Hirz; Pan Tong; Jing Wang; Jaime Rodriguez-Canales; Pamela A Villalobos; Edwin R Parra; Neda Kalhor; Lynette M Sholl; Jennifer L Sauter; Achim A Jungbluth; Mari Mino-Kenudson; Roxana Azimi; Yasir Y Elamin; Jianjun Zhang; Giulia C Leonardi; Fei Jiang; Kwok-Kin Wong; J Jack Lee; Vassiliki A Papadimitrakopoulou; Ignacio I Wistuba; Vincent A Miller; Garrett M Frampton; Jedd D Wolchok; Alice T Shaw; Pasi A Jänne; Philip J Stephens; Charles M Rudin; William J Geese; Lee A Albacker; John V Heymach
Journal:  Cancer Discov       Date:  2018-05-17       Impact factor: 39.397

5.  Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Authors:  Giuseppe Lo Russo; Massimo Moro; Michele Sommariva; Valeria Cancila; Mattia Boeri; Giovanni Centonze; Simona Ferro; Monica Ganzinelli; Patrizia Gasparini; Veronica Huber; Massimo Milione; Luca Porcu; Claudia Proto; Giancarlo Pruneri; Diego Signorelli; Sabina Sangaletti; Lucia Sfondrini; Chiara Storti; Elena Tassi; Alberto Bardelli; Silvia Marsoni; Valter Torri; Claudio Tripodo; Mario Paolo Colombo; Andrea Anichini; Licia Rivoltini; Andrea Balsari; Gabriella Sozzi; Marina Chiara Garassino
Journal:  Clin Cancer Res       Date:  2018-09-11       Impact factor: 12.531

6.  Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Authors:  E Saâda-Bouzid; C Defaucheux; A Karabajakian; V P Coloma; V Servois; X Paoletti; C Even; J Fayette; J Guigay; D Loirat; F Peyrade; M Alt; J Gal; C Le Tourneau
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

7.  Effects of conventional therapeutic interventions on the number and function of regulatory T cells.

Authors:  Mario Roselli; Vittore Cereda; Maria Giovanna di Bari; Vincenzo Formica; Antonella Spila; Caroline Jochems; Benedetto Farsaci; Renee Donahue; James L Gulley; Jeffrey Schlom; Fiorella Guadagni
Journal:  Oncoimmunology       Date:  2013-10-01       Impact factor: 8.110

Review 8.  Keap1-Nrf2 pathway: A promising target towards lung cancer prevention and therapeutics.

Authors:  Ying-Hui Tong; Bo Zhang; Yun Fan; Neng-Ming Lin
Journal:  Chronic Dis Transl Med       Date:  2015-10-22

9.  Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.

Authors:  Rodrigo Romero; Volkan I Sayin; Shawn M Davidson; Matthew R Bauer; Simranjit X Singh; Sarah E LeBoeuf; Triantafyllia R Karakousi; Donald C Ellis; Arjun Bhutkar; Francisco J Sánchez-Rivera; Lakshmipriya Subbaraj; Britney Martinez; Roderick T Bronson; Justin R Prigge; Edward E Schmidt; Craig J Thomas; Chandra Goparaju; Angela Davies; Igor Dolgalev; Adriana Heguy; Viola Allaj; John T Poirier; Andre L Moreira; Charles M Rudin; Harvey I Pass; Matthew G Vander Heiden; Tyler Jacks; Thales Papagiannakopoulos
Journal:  Nat Med       Date:  2017-10-02       Impact factor: 53.440

Review 10.  Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.

Authors:  Viktor Fleming; Xiaoying Hu; Rebekka Weber; Vasyl Nagibin; Christopher Groth; Peter Altevogt; Jochen Utikal; Viktor Umansky
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

View more
  2 in total

Review 1.  Hyperprogression Under Immune Checkpoint-Based Immunotherapy-Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model.

Authors:  Mikolaj Kocikowski; Katarzyna Dziubek; Maciej Parys
Journal:  Cancers (Basel)       Date:  2020-03-27       Impact factor: 6.639

2.  Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade.

Authors:  Pranjal Vaidya; Kaustav Bera; Pradnya D Patil; Amit Gupta; Prantesh Jain; Mehdi Alilou; Mohammadhadi Khorrami; Vamsidhar Velcheti; Anant Madabhushi
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.